Pictor is set to introduce its PictArray SARS-CoV-2 IgG enzyme-linked immunosorbent assay (ELISA) antibody test in New Zealand.
The company will collaborate with Rako Science to provide improved access to Covid-19 antibody testing in the country using Tasso technology.
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
The Covid-19 antibody test will be accessible through Tasso’s remote blood collection device and new Tasso+ in-clinic collections.
New Zealanders and healthcare organisations will be able to access the ELISA antibody test from Rako Science.
Initially, Rako Science will provide supervised in-centre testing from two locations in Christchurch and Auckland.
Claimed to be the first of its kind, the PictArray SARS-CoV-2 ELISA assay has been designed for detecting if a patient’s body generates an immune response to Covid-19.
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalDataIt can also detect if a patient has antibodies from a previous SARS-CoV-2 infection, from spike protein (SP) and nucleocapsid protein (NP) antibodies, or from vaccination alone, which generates SP antibodies only.
This test will help indicate whether patients who are at risk were not able to mount a detectable antibody response despite vaccination or infection (SP and NP negative).
Pictor CEO Howard Moore said: “The ability to test for SP, NP and a combination of SP and NP allows us to understand an individual’s circulating antibodies.
“That way, the patient and their doctor will know whether the patient should be immunised or boosted.”
The PictArray SARS-CoV-2 ELISA assay helps to guide personalised clinical interventions and inform broader measures related to public health.
In June, Pictor obtained CE mark for the PictArray SARS-CoV-2 IgG ELISA antibody test.
